Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Sutro Biopharma's share price for the quarter that ended in Mar. 2026 was €6.235. Sutro Biopharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 16.57 Mil. Therefore, Sutro Biopharma's market cap for the quarter that ended in Mar. 2026 was €103.30 Mil.
Sutro Biopharma's quarterly market cap
declined
from Sep. 2025 (€64.04 Mil) to Dec. 2025 (€53.52 Mil) but then
increased
from Dec. 2025 (€53.52 Mil) to Mar. 2026 (€103.30 Mil).
Sutro Biopharma's annual market cap
declined
from Dec. 2023 (€236.72 Mil) to Dec. 2024 (€146.90 Mil) and
declined
from Dec. 2024 (€146.90 Mil) to Dec. 2025 (€53.52 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sutro Biopharma's Enterprise Value for Today is €183.95 Mil.
Sutro Biopharma (STU:S090) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sutro Biopharma Market Cap Related Terms
Sutro Biopharma Market Cap Historical Data
* Premium members only.
The historical data trend for Sutro Biopharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:S090 vs AVIR, IPSC, CCCC: Market Cap Comparison
For the Biotechnology subindustry, Sutro Biopharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Sutro Biopharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma (STU:S090) has a Market Cap of €349.76 Mil as of Jul. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sutro Biopharma and its competitors. According to the industry distribution chart, Sutro Biopharma ranks #446 out of 1420 companies in the Biotechnology industry, placing it in the top 31.4%.
Is Sutro Biopharma's Market Cap too high?
Sutro Biopharma's current Market Cap is €349.76 Mil. Based on the distribution chart, Sutro Biopharma ranks #446 out of 1420 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sutro Biopharma has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Market Cap compare to AVIR and IPSC?
According to the Biotechnology industry distribution chart, Sutro Biopharma ranks #446 out of 1420 companies for Market Cap. This puts Sutro Biopharma in the upper half of its industry. The industry median Market Cap is 111.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 111.98, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sutro Biopharma and its competitors. For the Biotechnology industry, the median Market Cap is 111.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sutro Biopharma's current Market Cap is €349.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Sutro Biopharma (STU:S090) has a current Market Cap of €349.76 Mil. The stock's GF Value™ is €3.14, compared to a current price of €6.24 — trading 98.6% above its estimated fair value. The current Market Cap is €349.76 Mil. Sutro Biopharma's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Sutro Biopharma (STU:S090), the current Market Cap is €349.76 Mil as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sutro Biopharma (STU:S090) Overvalued in 2026?
Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued.
The current stock price of €6.24 is trading 98.6% above its estimated GF Value™ of €3.14.
Key valuation signals for STU:S090:
Market Cap: €349.76 Mil
GF Value™: €3.14 vs. price of €6.24 (98.6% above fair value)
No single metric tells the full story. See the STU:S090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
47GF Score
Get the complete analysis for STU:S090
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:S090 has been successfully added to your 
